Myovant Sciences Ltd $ 22.10 -0.425 (-1.89%)
Volume:
505,565
Avg Vol (1m):
1,299,592
Market Cap $:
2.01 Bil
Enterprise Value $:
1.59 Bil
PE Ratio:
0.00
PB Ratio:
0.00
Financial Strength | 2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 2.29 | ||
| Equity-to-Asset | -0.35 | ||
| Debt-to-Equity | -1.2 | ||
| Debt-to-EBITDA | -1.42 | ||
| Piotroski F-Score | 5 | ||
| Altman Z-Score | -0.73 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -714.39 | ||
| Net Margin % | -687.61 | ||
| ROA % | -93.81 | ||
| ROC (Joel Greenblatt) % | -1725.59 | ||
| 3-Year EBITDA Growth Rate | -23.4 | ||
| 3-Year EPS without NRI Growth Rate | -25.6 |
MYOV
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PS Ratio | 57.02 | ||
| Price-to-Free-Cash-Flow | 4.51 | ||
| Price-to-Operating-Cash-Flow | 4.5 | ||
| EV-to-EBIT | -6.86 | ||
| EV-to-EBITDA | -6.93 | ||
| EV-to-Revenue | 45.76 | ||
| Current Ratio | 2.99 | ||
| Quick Ratio | 2.99 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.2 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Earnings Yield (Greenblatt) % | -14.52 |